Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
NASA launches science balloon in Antarctica | Space photo of the day for Dec. 22, 2025 - 2Ten Awesome Authentic Realities That Will Leave You Interested
- 3Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- 4Defense Minister Katz moves to extend IDF service to 36 months
- 54 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
- No red, no long shorts: The fashion rules Joe Burrows lives by
- At least 7 dead as Israel renews attacks on Beirut and across Lebanon
- Find the Effect of Web-based Entertainment on Psychological wellness: Exploring the Advanced Scene Securely
- Scientists are getting our robotic explorers ready to help send humans to Mars
- Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- Moderna to complete US mRNA manufacturing network with $140 million investment
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- One-third of asylum applications by Iranians approved in Germany
- 'Always put others first': IDF reservist who died while on leave saves four with organ transplants
